Retama para laxative
Senna reticulata — 7 estudios científicos revisados
Preliminary¿Sirve Retama para laxative?
La investigación científica ha explorado el potencial de Retama (Senna reticulata) en relación con laxative. Se han identificado 7 estudios relevantes que examinan esta relación.
Compuestos activos involucrados: Alcaloides, Fenoles, Flavonoides, Glucósidos, Polifenoles, Saponinas, Terpenos, Compuestos fenólicos
Evidencia Científica
Los siguientes estudios han investigado la relación entre Retama y laxative:
American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation.
INTRODUCTION: Chronic idiopathic constipation (CIC) is a common disorder associated with significant impairment in quality of life. This clinical practice guideline, jointly developed by the American Gastroenterological Association and the American College of Gastroenterology, aims to inform clinicians and patients by providing evidence-based practice recommendations for the pharmacological treatment of CIC in adults. METHODS: The American Gastroenterological Association and the American College of Gastroenterology formed a multidisciplinary guideline panel that conducted systematic reviews of
PubMed: 37211380American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation.
INTRODUCTION: Chronic idiopathic constipation (CIC) is a common disorder associated with significant impairment in quality of life. This clinical practice guideline, jointly developed by the American Gastroenterological Association and the American College of Gastroenterology, aims to inform clinicians and patients by providing evidence-based practice recommendations for the pharmacological treatment of CIC in adults. METHODS: The American Gastroenterological Association and the American College of Gastroenterology formed a multidisciplinary guideline panel that conducted systematic reviews of
PubMed: 37204227Senna Versus Magnesium Oxide for the Treatment of Chronic Constipation: A Randomized, Placebo-Controlled Trial.
INTRODUCTION: This is the first prospective, double-blinded, randomized, placebo-controlled trial to evaluate the safety and efficacy of a stimulant laxative compared with an osmotic agent for the treatment of chronic idiopathic constipation. METHODS: Patients were randomly administered stimulant laxative (senna, 1.0 g), osmotic agent (magnesium oxide [MgO], 1.5 g), or placebo for 28 consecutive days. The primary endpoint was overall symptom improvement. Secondary endpoints were spontaneous bowel movement (SBM), complete SBM, and patient assessment of constipation quality of life (QOL). RESULT
PubMed: 32969946Senna alata.
A review is made of chemical, ethnopharmacological and pharmacological papers dealing with Senna alata (L.) Roxb., a plant that belongs to the Creole traditional system of medicine and that has recently been introduced in the French Pharmacopoeia. The proofs existing for its various usages are presented. The species is mainly used against constipation and skin diseases. The laxative activity is supported by scientific findings. In contrast the dermatologic use requires further investigation.
PubMed: 19446609Constipation in adults.
INTRODUCTION: Although there are defined criteria for the diagnosis of constipation, in practice, diagnostic criteria are less rigid, and in part depend on the perception of normal bowel habit. Constipation is highly prevalent, with approximately 12 million general practitioner prescriptions for laxatives in England in 2001. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of non-drug interventions, and of other interventions, in adults with idiopathic chronic constipation? We searched: Medline, Embase, The Cochra
PubMed: 19454117Seguridad y Precauciones
La seguridad en el uso de Senna reticulata es un asunto de extrema precaución debido a su potente actividad farmacológica y la presencia de compuestos bioactivos como los glucósidos antraquinónicos. En mujeres embarazadas, el uso de esta planta es estrictamente desaconsejado; los componentes de la especie pueden actuar como agentes oxitócicos, estimulando las contracciones del músculo liso uterino, lo que incrementa el riesgo de parto pretérmino o aborto espontáneo. Durante la lactancia, los metabolitos activos pueden ser excretados a través de la leche materna, lo que representa un riesgo de diarreas profusas y desequilibrio electrolítico en el lactante. En la población pediátrica menor de 12 años, el riesgo de desequilibrio electrolítico es crítico, ya que la pérdida de líquidos puede derivar en una deshidratación aguda y una disminución peligrosa de los niveles de potasio y sodio. En cuanto a las interacciones medicamentosas, la Retama puede interferir con la warfarina debido a que la aceleración del tránsito intestinal altera la ventana de absorción del anticoagulante, modificando su biodisponibilidad y eficacia. Con la metformina, la alteración de la motilidad intestinal puede comprometer la absorción constante del fármaco, afectando el control glucémico.
Otras plantas estudiadas para laxative
Perfil completo: Ver todos los usos y evidencia de Retama →